Multiple Sclerosis

Group leader

Luisa María Villar Guimerans

luisamaria.villar(ELIMINAR)@salud.madrid.org

Tlf.: 0034 913368029

Principal Investigator

  • Enric Monreal Laguillo
  • Juan Luis Chico Garcia
  • José Ignacio Fernández Velasco

Collaborating Staff

  • María Mercedes Espiño Martínez
  • Ernesto Roldán Santiago
  • Lucienne Costa-Frossard França
  • Susana Sainz de la Maza Cantero
  • Noelia Villarrubia Migallón
  • Roberto Pariente Rodríguez
  • Alexander Rodero Romero
  • Fernando Rodríguez Jorge
  • José Luis Veiga González
  • Eulalia Rodríguez Martín
  • Zahara Garcia de Castro
  • Cristina Saavedra Pérez
  • Marta Selva Giménez
  • Marina Pérez Pleite
  • Enrique García Barrera
Imagen equipo

Group leader

Luisa María Villar Guimerans

luisamaria.villar(ELIMINAR)@salud.madrid.org

Tlf.: 0034 913368029

Principal Investigator

  • Enric Monreal Laguillo
  • Juan Luis Chico Garcia
  • José Ignacio Fernández Velasco

Collaborating Staff

  • María Mercedes Espiño Martínez
  • Ernesto Roldán Santiago
  • Lucienne Costa-Frossard França
  • Susana Sainz de la Maza Cantero
  • Noelia Villarrubia Migallón
  • Roberto Pariente Rodríguez
  • Alexander Rodero Romero
  • Fernando Rodríguez Jorge
  • José Luis Veiga González
  • Eulalia Rodríguez Martín
  • Zahara Garcia de Castro
  • Cristina Saavedra Pérez
  • Marta Selva Giménez
  • Marina Pérez Pleite
  • Enrique García Barrera

Strategic Objectives

  • To delve deeper into the study of the pathophysiological mechanisms of MS.
  • To study the mechanisms associated with the progressive forms of the disease.
  • To identify immunological factors that predict the early risk of MS progression in order to establish personalized therapy for this disease.
  • To evaluate biomarkers of treatment response and identify patients at risk of serious side effects.
  • To study modifiable environmental factors that play a role in the course of the disease.

Research Lines

  • Study of the pathological mechanisms in MS.
  • Search for biomarkers that identify the best benefit/risk profile for different biological therapies in MS.
  • Search for biomarkers that identify the risk of progression in MS.
  • Immunological mechanisms associated with primarily progressive forms of MS.
  • Association of antibodies against the Epstein-Barr virus and the clinical and immunological phenotype in MS.

Location

Ramón y Cajal University Hospital

Laboratory: Immunology Department, Floor -1, Left

Clinical Unit: Neurology Department, Floor -2, Center

Keywords

Multiple Sclerosis (MS), biomarkers, immunological mechanisms, B cells, antibodies